Rayvow (lasmiditan)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- lasmiditan
- Company
- Eli Lilly Nederland B.V.
- Status
- Authorised
- Therapeutic area
- Migraine Disorders
- CHMP opinion
- Thu 16 Dec 2021
- EU approval
- Wed 17 Aug 2022
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005332
- ATC
- N02CC08
- Official record
- www.ema.europa.eu
Indication
RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.
Regulatory milestones
No milestones recorded in the last year.
Follow Rayvow
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.